拓展靶向放射性核素治疗视野:免疫治疗联合与FAP靶向策略
本文综述靶向放射性核素治疗(TRT)的免疫调节作用及与免疫检查点抑制剂(ICI)联合的原理,重点讨论FAP-TRT靶向肿瘤相关成纤维细胞(CAF)重塑肿瘤微环境、将「冷」肿瘤转为「热」表型的潜力,并指出剂量、序贯、靶点选择等挑战。
要点
- TRT与EBRT类似具有免疫调节作用,可重塑肿瘤免疫微环境,为联合ICI提供依据。
- FAP-TRT靶向CAF而非直接靶向肿瘤细胞,可能增强放射免疫调节效应。
- 临床前模型显示FAP-TRT与ICI有协同作用,但剂量、序贯和靶点选择等挑战仍存。
核心结论
- TRT与免疫治疗尤其是FAP-TRT联合是精准肿瘤学有前景的方向,值得进一步转化和临床研究。
研究设计与样本
- 本文为综述,汇总EBRT或TRT的免疫效应及TRT联合ICI的临床前与临床研究证据。
主要发现
- TRT与EBRT均可重塑肿瘤免疫微环境,联合ICI可发挥协同效应并减轻免疫抑制机制。
- FAP-TRT靶向CAF,可调节肿瘤微环境、将「冷」肿瘤转为「热」表型并增强免疫浸润。
- 临床前模型显示FAP-TRT与ICI协同,但需明确其对CAF亚群的影响并优化放射性药物设计。
临床怎么用
- TRT与ICI联合时需综合考虑辐射剂量与分次、治疗序贯、靶点选择及免疫治疗/放射性药物选择。
- FAP-TRT通过靶向CAF调节微环境,可能拓展联合免疫治疗的适用人群。
局限性
- FAP-TRT对CAF亚群的作用尚未明确。
- 放射性药物设计仍需优化。
- TRT/EBRT联合ICI共有的剂量、序贯和靶点选择问题尚待解决。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted radionuclide therapy (TRT) has emerged as a promising cancer treatment modality and is increasingly recognized as an immunomodulatory tool, similar to external beam radiotherapy (EBRT). Both forms of radiation can reshape the tumor immune microenvironment, providing a rationale for their combination with immune checkpoint inhibitors (ICIs) to harness synergistic effects while mitigating immunosuppressive mechanisms. Outcomes of such combinations depend on radiation dose/fractionation, treatment sequencing, target selection, and the choice of immunotherapeutic/radiopharmaceutical agents. Among novel TRT strategies, fibroblast activation protein-TRT (FAP-TRT) stands out for its targeting of cancer-associated fibroblasts (CAFs), key components of the tumor stroma involved in immune evasion and therapy resistance. Unlike conventional TRTs that directly target tumor cells, FAP-TRT acts on CAFs, potentially modulating the tumor microenvironment to enhance the immunomodulatory effects of radiation. This review examines the immunological effects of radiation-via EBRT or TRT-and the rationale for combining TRT with ICIs. We highlight preclinical and clinical studies demonstrating both the synergistic potential and context-specific limitations of TRT-ICI combinations. Emphasis is placed on the emerging role of FAP-TRT in remodeling the tumor microenvironment, converting "cold" tumors into "hot" phenotypes, and enhancing immune infiltration. Preclinical models show synergy between FAP-TRT and ICIs, but challenges remain, including clarifying FAP-TRT's effects on CAF subpopulations, optimizing radiopharmaceutical design, and addressing shared issues with TRT/EBRT-ICI combinations, such as dosing, sequencing, and target selection. The integration of TRT and immunotherapy-particularly FAP-TRT combinations-offers a compelling avenue for precision oncology and warrants further translational and clinical investigation.
引用
- Öztürk AA, Delbart W, Flamen P, et al. Expanding the Horizon of Targeted Radionuclide Therapy: Immunotherapy Combinations and FAP-Targeted Approaches. Semin Nucl Med. 2025. PMID: 40987691. doi:10.1053/j.semnuclmed.2025.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。